Article Details

Jazz and Roche's Zepzelca-Tecentriq wins FDA ES-SCLC approval

Retrieved on: 2025-10-03 16:57:50

Tags for this article:

Click the tags to see associated articles and topics

Jazz and Roche's Zepzelca-Tecentriq wins FDA ES-SCLC approval. View article details on hiswai:

Excerpt

Roche and Jazz's combination is now the first and only approved dual maintenance therapy for ES-SCLC, rivaling AZ's Imfinzi in this setting.

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo